Business
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting
FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived
About this update from Celularity Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro. Oral and Poster PresentationTitle: Decellularized Dehydrated Human Amniotic Membranes Support the Cellular Functions of Human Tenocytes in VitroAbstract number: TBDSession: Bioactive materials for hard and/or soft tissue regenerationPresenter: Anna Gosiewska, Ph.D., Vice President Research & Development, Degenerative Diseases, Celularity Inc.Location: Sheraton San Diego Hotel and Marina, San Diego, CADate and Time: April 19, 2023 3:45-4:00pm; Presentation Slot: 5Poster Session: Poster Session 1 (P1) April 19, 2023; Poster Session 2 (P2), April 20, 2023 and Poster Session 3 (P3) April 21, 2023. “We look forward to the upcoming SFB annual meeting and presenting our most current biomaterials research,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “Celularity’s unique technology platform is grounded in our use of the post-partum placenta as the source of cells and biomaterials for the development of therapeutics. This creates two independent but complimentary product opportunities in cellular and regenerative medicine, which reinforces our confidence in potential therapeutic benefits of biomaterials as we advance the development of these therapeutic options for patients,” said Hariri. About Celularity Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. These therapeutic programs target indications in autoimmune, infectious and degenerative diseases, and cancer. In addition, Celularity develops, man...